Sales & Marketing

Gregg Fisher reflects on how this brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.

With healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging-or create their own.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian.

Experts say knowing how to lead in uncertain times and being open to change is just as important as a degree.

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year-why they were chosen and the challenges, changes, and successes since.

The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach-as pharmas look to close the conversation gaps between patients and healthcare providers.

Charles Benaiah, CEO of New York's watzan, tells Pharm Exec that the key to effective social media marketing is personalization.

A review of some of the sales strategy insights on offer at last month’s eyeforpharma Barcelona event.

Stan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.

What many in our industry may overlook as they try to identify some new trend are the changes that move below our feet. And they have the potential to disrupt even the most thoughtful marketing plans, writes Al Topin.

In the brave new world of personalized medicine, there are concerns that the one-drug-fits-all mass-marketing approach of the past won’t work, writes Peter Houston.

It's time to take advantage of a nascent technology embrace taking hold among market insights professionals, writes Janet Kolsoff.

Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week.

A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.

It’s safe to say content marketing is here to stay, writes Peter Houston. So what is pharma doing with it?

Gary Kaplan offers surveying tips to help identify both tactical and strategic initiatives required for a true key performance indicator.

Last month Microsoft bought LinkedIn. What does this mean for pharm execs using the platform? Peter Houston reports.

A new educational and potential prognosis tool for the treatment of multiple sclerosis shows how an accessible, easy-to-see visualization of disease state can serve as the threshold for fresh clinical insight-all geared to the individual patient.